CDiddy, If CYDY does in fact slow or stop metas
Post# of 154134
(Total Views: 475)
Posted On: 11/16/2019 4:00:46 PM
CDiddy,
Absolutely, I was trying to make a comparison with the other drugs. If Leronlimab goes "general" for Oncology I think that what Nader said about being the next Humira (or Keytruda today that displaced Humira as the most successful drug) will come true.
BTW, Keytruda sales have grown from $55 million in 2014 to $7.2 billion in 2018. This represents an overall growth of 130x, and an average annual growth of 334%
No, it refers to the Price/sales term. It is used in some valuation models and it means that the average stock price as relates to the company sales is 12.9 for the biotech Industry (in average). This is just an approximation since, as you understand, some companies don't have sales and have a stock price, and others have lots of sales and have a smaller number. For example Amgen has 4.11 and say, Idera Pharmaceuticals is 78.1
I took the average for the industry for calculation purpose's sake. If a company is perceived to have a bright future the price to sales goes up considerably.
I liked your post about what we can call CYDY's obsessive syndrome ... I think I am suffering of a chronic stage of the condition
Quote:
If CYDY does in fact slow or stop metastisis in many or all types of cancer, doesn't it stand to reason it would move toward or to the top of this list?
Absolutely, I was trying to make a comparison with the other drugs. If Leronlimab goes "general" for Oncology I think that what Nader said about being the next Humira (or Keytruda today that displaced Humira as the most successful drug) will come true.
BTW, Keytruda sales have grown from $55 million in 2014 to $7.2 billion in 2018. This represents an overall growth of 130x, and an average annual growth of 334%
Quote:
In your calculation you are using a 12.9 multiple. If this is the average life of the patent, wouldn't the multiple need to be discounted from this?
No, it refers to the Price/sales term. It is used in some valuation models and it means that the average stock price as relates to the company sales is 12.9 for the biotech Industry (in average). This is just an approximation since, as you understand, some companies don't have sales and have a stock price, and others have lots of sales and have a smaller number. For example Amgen has 4.11 and say, Idera Pharmaceuticals is 78.1
I took the average for the industry for calculation purpose's sake. If a company is perceived to have a bright future the price to sales goes up considerably.
I liked your post about what we can call CYDY's obsessive syndrome ... I think I am suffering of a chronic stage of the condition
(3)
(0)